Liraglutide: Reference Overview and Reconstitution Notes

Liraglutide

What it is

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, structurally an acylated analog of the human GLP-1(7-37) backbone. It is a single-chain peptide of roughly 31 amino acids (about 3,751 Da) carrying a C16 fatty-acid (palmitoyl) side chain attached through a gamma-glutamic acid spacer, a modification that promotes reversible albumin binding and slows enzymatic breakdown.

Research context and categorization

Liraglutide is grouped under the metabolic and weight-regulation category of peptides. As a GLP-1 receptor agonist it is commonly discussed in relation to glucose regulation, appetite and satiety signaling, and body-weight management, and it is often studied in the context of the broader incretin and GLP-1 pathway. In the research and clinical literature it has been investigated for glycemic control in type 2 diabetes, for chronic weight management, and for cardiovascular outcome endpoints. Because liraglutide is one of the FDA-approved members of this class for specific indications, some of these uses are established for the approved medical products, while any application outside those approved indications, or any use of research-supply material, remains investigational and is not a confirmed or approved benefit.

Status

  • Regulatory status: FDA-approved for specific indications. Liraglutide is the active ingredient in approved products for type 2 diabetes glycemic control (first approved 2010, with a later indication related to cardiovascular risk reduction in certain patients) and for chronic weight management (first approved 2014, later extended to certain adolescents). Material sold for laboratory use is labeled research-only, is not an approved drug product, and is not for human or animal use.
  • Sport status: Not specifically listed on the WADA Prohibited List. GLP-1 receptor agonists as a class have drawn WADA attention, and related compounds in the class have appeared on the WADA Monitoring Program, but liraglutide is not named as a prohibited substance on the current List. Status can change when WADA updates the List each year, so anyone competing under anti-doping rules should confirm the current List and any sport-specific policy directly.

Reconstitution notes (general)

Research-grade liraglutide is typically supplied as a lyophilized (freeze-dried) powder that is reconstituted with bacteriostatic water before use. The resulting concentration equals the milligrams of peptide in the vial divided by the millilitres of bacteriostatic water added. For example, 5 mg of powder reconstituted with 2 mL of water gives 2.5 mg/mL. Adjust the water volume to reach the working concentration you want, and use the calculator at our reconstitution and blend calculators to confirm the arithmetic.

Dilution and handling notes (compound-specific)

Liraglutide is one of the more formulation-sensitive GLP-1 peptides, and its behavior is driven by the C16 fatty-acid chain. Note a key distinction first: the commercial finished product ships as a ready-to-use aqueous liquid in prefilled pens, formulated at an elevated pH (reported around pH 8) precisely because liraglutide's water solubility is strongly pH-dependent. If you encounter liraglutide as a lyophilized powder, it is research-supply material rather than the finished drug, and the points below apply.

  • pH-dependent solubility. Liraglutide is freely soluble under mildly alkaline conditions but solubility drops sharply below roughly neutral pH, reaching a minimum around pH 4 to 5. Standard bacteriostatic water (0.9% benzyl alcohol) sits near neutral, so concentrated preparations can look hazy or cloudy. This reflects a property of the molecule and is not necessarily a sign of degradation.
  • Self-association. The fatty-acid chain drives liraglutide to self-associate into micelle-like oligomers, and the degree of association shifts with concentration and pH near neutrality, so appearance can vary between preparations.
  • Aggregation under mechanical stress. Vigorous shaking can nucleate fibrils and larger aggregates and also promotes foaming, which the fatty-acid chain makes worse. The practical fix is to direct the diluent slowly down the inner wall of the vial and to swirl or roll gently rather than shake.
  • Working concentration. Because solubility is limited, lower, more dilute preparations tend to stay clearer and easier to handle than highly concentrated ones. Choose a water volume that keeps the solution manageable rather than pushing the milligrams into a very small volume. Aliquot working volumes to minimize repeated freeze-thaw cycles.

Handling and storage

Refrigerate reconstituted solution at 2 to 8 C and keep it out of direct light. Wipe the vial stopper with an alcohol swab before each draw, and label the vial with the reconstitution (mix) date. A reconstituted peptide is generally treated as having roughly a four-week refrigerated working window. Discard the solution if it becomes discolored, develops floaters or particulate, or turns cloudy in a way that does not resolve. With liraglutide, note that a faint haze can reflect its normal pH-dependent solubility, so weigh appearance together with storage age rather than on cloudiness alone.

Related reading

Tools and supplies

For laboratory and research reference only. Educational content, not medical, dosing, injection, or therapeutic guidance, and not intended for human or animal use. Any research uses described are investigational and not confirmed or approved benefits. Confirm anything involving health with a licensed professional. References linked above.